GlassScriptPhysician profile
Amanda J Worner
NPI 1780014944
$6,338.93
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,844 · 2022: $1,417 · 2023: $2,901 · 2024: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.34 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $933.14 | 2021-2023 | Airsupra, Farxiga, Bevespi Aerosphere |
| Abbvie INC. | $908.03 | 2021-2024 | |
| Novo Nordisk INC | $573.57 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $500.58 | 2021-2024 | |
| Amgen INC. | $357.28 | 2021-2023 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $335.36 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $307.46 | 2021-2023 | Rexulti |
| Pfizer INC. | $248.50 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.73 | 2021-2023 | Synjardy, Tradjenta, Jardiance |
| Ascensia Diabetes Care US INC. | $219.73 | 2023 | |
| Janssen Pharmaceuticals, INC | $156.31 | 2021-2023 | Invega Sustenna, Xarelto |
| Sumitomo Pharma America, INC. | $140.81 | 2023-2024 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $140.27 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.95 | 2021-2023 | Trintellix |
| Ironwood Pharmaceuticals, INC | $100.74 | 2023-2024 | Linzess |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Worner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.